Cargando…
Efforts to maximize the potential of CAR-T therapy for cancer, from T-bodies to CAR-immune cells
Autor principal: | Fujiwara, Hiroshi |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Singapore
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8436850/ https://www.ncbi.nlm.nih.gov/pubmed/34515988 http://dx.doi.org/10.1007/s12185-021-03213-8 |
Ejemplares similares
-
Engineering the next generation of CAR-NK immunotherapies
por: Biederstädt, Alexander, et al.
Publicado: (2021) -
Development of CMV-CD19 bi-specific CAR T cells with post-infusion in vivo boost using an anti-CMV vaccine
por: Wang, Xiuli, et al.
Publicado: (2021) -
Cytopenias following anti-CD19 chimeric antigen receptor (CAR) T cell therapy: a systematic analysis for contributing factors
por: Xia, Yuan, et al.
Publicado: (2022) -
Blinatumomab as salvage therapy in patients with relapsed/refractory B-ALL who have failed/progressed after anti-CD19-CAR T therapy
por: Qi, Yao, et al.
Publicado: (2023) -
Body iron metabolism and pathophysiology of iron overload
por: Kohgo, Yutaka, et al.
Publicado: (2008)